[HTML][HTML] Tumor mutational burden in colorectal cancer: implications for treatment

A Marques, P Cavaco, C Torre, B Sepodes… - Critical Reviews in …, 2024 - Elsevier
Although immune checkpoint inhibitors have revolutionized the treatment of several
advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative …

Evaluation of the efficacy and safety of first-and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta …

K Chen, W Chen, R Yue, D Zhu, S Cui… - Frontiers in …, 2024 - frontiersin.org
Background A multitude of randomized controlled trials (RCTs) conducted in both the initial
and subsequent treatment settings for patients diagnosed with metastatic colorectal cancer …

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer

L Yang, S Liu, W He, Z **ong, L **a - BMC cancer, 2023 - Springer
Background Large-scale genomic alterations, especially CD274/PD-L1 gene amplification,
have great impact on anti-PD-1 efficacy on cancers such as Hodgkin's lymphoma. However …

免疫检查点抑制剂治疗转移性结直肠癌的研究进展

涂娟娟, 金志明 - 上海交通大学学报 (医学版), 2023 - xuebao.shsmu.edu.cn
结直肠癌(colorectal cancer, CRC) 是我国乃至全世界常见的恶性肿瘤, 转移事件发生率高.
免疫治疗在转移性结直肠癌(metastatic CRC, mCRC) 的治疗中作为一种新兴的治疗方法 …

Research progress of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer

TU Juanjuan, JIN Zhiming - Journal of Shanghai Jiao Tong …, 2023 - xuebao.shsmu.edu.cn
Colorectal cancer (CRC) is a common malignancy with a high incidence of metastatic events
in China and the world. Immunotherapy has received increasing attention as an emerging …

[CITAT][C] Should surgical strategies be suspended in case of tumor response to immunotherapy?

M Pocard, C Sabbagh - Surgery Open Digestive Advance, 2021 - Elsevier